Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Amortizatization of Intangibles (2021 - 2025)

Historic Amortizatization of Intangibles for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $22000.0.

  • SAB Biotherapeutics' Amortizatization of Intangibles changed 0.0% to $22000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $85344.0, marking a year-over-year decrease of 4590.71%. This contributed to the annual value of $237093.0 for FY2024, which is 13709.3% up from last year.
  • SAB Biotherapeutics' Amortizatization of Intangibles amounted to $22000.0 in Q3 2025, which was down 0.0% from $22000.0 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Amortizatization of Intangibles registered a high of $83994.0 during Q1 2024, and its lowest value of $19344.0 during Q4 2024.
  • Its 5-year average for Amortizatization of Intangibles is $31607.8, with a median of $24717.0 in 2022.
  • In the last 5 years, SAB Biotherapeutics' Amortizatization of Intangibles soared by 23597.6% in 2024 and then crashed by 7380.77% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Amortizatization of Intangibles (Quarter) stood at $41206.0 in 2021, then crashed by 40.02% to $24716.0 in 2022, then grew by 20.48% to $29779.0 in 2023, then plummeted by 35.04% to $19344.0 in 2024, then grew by 13.73% to $22000.0 in 2025.
  • Its Amortizatization of Intangibles was $22000.0 in Q3 2025, compared to $22000.0 in Q2 2025 and $22000.0 in Q1 2025.